Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Berglund EG"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Coppola P; Certara Drug Development Solutions, Milan, Italy., Berglund EG; Certara Drug Development Solutions, Oss, The Netherlands., Rowland Yeo K; Certara UK Limited (Simcyp Division), Sheffield, UK.
Publikováno v:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2024 Nov; Vol. 13 (11), pp. 1830-1834. Date of Electronic Publication: 2024 Oct 14.
Autor:
Johnson TN; Certara UK Limited Simcyp Division, Sheffield, UK., Small BG; Certara UK Limited Simcyp Division, Sheffield, UK., Berglund EG; Certara Integrated Drug Development, Oss, The Netherlands., Rowland Yeo K; Certara UK Limited Simcyp Division, Sheffield, UK.
Publikováno v:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2021 Sep; Vol. 10 (9), pp. 967-972. Date of Electronic Publication: 2021 Jul 20.
Autor:
McFeely SJ; University of Washington Drug Interaction Solutions, Seattle, Washington, USA., Ritchie TK; University of Washington Drug Interaction Solutions, Seattle, Washington, USA., Yu J; University of Washington Drug Interaction Solutions, Seattle, Washington, USA., Nordmark A; Scandinavian Development Services, Danderyd, Sweden., Berglund EG; Certara Strategic Consulting, Integrated Drug Development, Oss, The Netherlands., Levy RH; University of Washington Drug Interaction Solutions, Seattle, Washington, USA., Ragueneau-Majlessi I; University of Washington Drug Interaction Solutions, Seattle, Washington, USA.
Publikováno v:
Journal of clinical pharmacology [J Clin Pharmacol] 2020 Aug; Vol. 60 (8), pp. 1087-1098. Date of Electronic Publication: 2020 Mar 20.
Autor:
Luzon E; European Medicines Agency (EMA), London, UK., Blake K; European Medicines Agency (EMA), London, UK., Cole S; Medicines and Healthcare products Regulatory Agency (MHRA), London, UK.; Pharmacokinetics Working Party (PKWP), EMA, London, UK.; Modelling and Simulation Working Group (MSWG), EMA, London, UK., Nordmark A; Modelling and Simulation Working Group (MSWG), EMA, London, UK.; Medical Products Agency (MPA), Uppsala, Sweden., Versantvoort C; Pharmacokinetics Working Party (PKWP), EMA, London, UK.; Medicines Evaluation Board (MEB), Utrecht, Netherlands., Berglund EG; Pharmacokinetics Working Party (PKWP), EMA, London, UK.; Medical Products Agency (MPA), Uppsala, Sweden.
Publikováno v:
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2017 Jul; Vol. 102 (1), pp. 98-105. Date of Electronic Publication: 2016 Dec 26.
Autor:
Hsu V; Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD, 20993, USA., de L T Vieira M; Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD, 20993, USA.; College of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil., Zhao P; Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD, 20993, USA. ping.zhao@fda.hhs.gov., Zhang L; Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD, 20993, USA., Zheng JH; Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD, 20993, USA., Nordmark A; Swedish Medical Products Agency, Uppsala, Sweden., Berglund EG; Swedish Medical Products Agency, Uppsala, Sweden., Giacomini KM; Department of Bioengineering and Therapeutic Sciences, Schools of Pharmacy and Medicine, University of California San Francisco, San Francisco, CA, USA., Huang SM; Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD, 20993, USA.
Publikováno v:
Clinical pharmacokinetics [Clin Pharmacokinet] 2014 Mar; Vol. 53 (3), pp. 283-293.
Autor:
Vieira ML; US Food and Drug Administration, Silver Spring, MD, USA., Kirby B; University of Washington, Seattle, WA, USA., Ragueneau-Majlessi I; University of Washington, Seattle, WA, USA., Galetin A; University of Manchester, Greater Manchester, UK., Chien JY; Eli Lilly and Company, Indianapolis, IN, USA., Einolf HJ; Novartis, East Hanover, NJ, USA., Fahmi OA; Pfizer Inc., Groton, CT, USA., Fischer V; AbbVie, North Chicago, IL, USA., Fretland A; Eli Lilly and Company, Indianapolis, IN, USA., Grime K; AstraZeneca Research and Development, Mölndal, Sweden., Hall SD; Eli Lilly and Company, Indianapolis, IN, USA., Higgs R; Eli Lilly and Company, Indianapolis, IN, USA., Plowchalk D; Pfizer Inc., Groton, CT, USA., Riley R; AstraZeneca Research and Development, Alderley Park, UK., Seibert E; Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT, USA., Skordos K; GlaxoSmithKline, Research Triangle Park, NC, USA., Snoeys J; Janssen Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium., Venkatakrishnan K; Millennium Pharmaceuticals, Cambridge, MA, USA., Waterhouse T; Eli Lilly and Company, Indianapolis, IN, USA., Obach RS; Pfizer Inc., Groton, CT, USA., Berglund EG; Medical Products Agency, Uppsala, Sweden., Zhang L; US Food and Drug Administration, Silver Spring, MD, USA., Zhao P; US Food and Drug Administration, Silver Spring, MD, USA., Reynolds KS; US Food and Drug Administration, Silver Spring, MD, USA., Huang SM; US Food and Drug Administration, Silver Spring, MD, USA.
Publikováno v:
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2014 Feb; Vol. 95 (2), pp. 189-98. Date of Electronic Publication: 2013 Sep 18.
Autor:
Tweedie D; Drug Metabolism and Pharmacokinetics, Boehringer Ingelheim Pharmaceuticals, Ridgefield, Connecticut, USA. donald.tweedie@boehringer-ingelheim.com, Polli JW, Berglund EG, Huang SM, Zhang L, Poirier A, Chu X, Feng B
Publikováno v:
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2013 Jul; Vol. 94 (1), pp. 113-25. Date of Electronic Publication: 2013 Apr 10.
Autor:
Pean E; European Medicines Agency, London, United Kingdom. Elias.Pean@ema.europa.eu, Klaar S, Berglund EG, Salmonson T, Borregaard J, Hofland KF, Ersbøll J, Abadie E, Giuliani R, Pignatti F
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2012 Sep 01; Vol. 18 (17), pp. 4491-7. Date of Electronic Publication: 2012 Jul 24.
Autor:
Vieira ML; Office of Clinical Pharmacology, Office of Translational Sciences, US Food and Drug Administration, Silver Spring, Maryland, USA., Zhao P, Berglund EG, Reynolds KS, Zhang L, Lesko LJ, Huang SM
Publikováno v:
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2012 Apr; Vol. 91 (4), pp. 700-8. Date of Electronic Publication: 2012 Mar 07.